Filtered By:
Condition: Thrombosis
Management: Hospitals
Countries: UK Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 23 results found since Jan 2013.
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Carotid artery disease: knowing the numbers
This article discusses the evidence outlining the epidemiology, measurement and surgical management of carotid artery stenosis that inform national guidelines. Vascular and non-vascular trainees should understand these guidelines because of the potentially debilitating or fatal consequences of untreated carotid stenosis.PMID:35938764 | DOI:10.12968/hmed.2022.0184
Source: British Journal of Hospital Medicine - August 8, 2022 Category: Internal Medicine Authors: Adam Heyes Alexander Crichton Sriram Rajagopalan Source Type: research
